Pharmaceutical

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE…

2 months ago

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE…

2 months ago

Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development

Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded…

2 months ago

Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development

Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded…

2 months ago

Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development

Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded…

2 months ago

Xenon to Report Q3 2025 Financial Results on November 3, 2025

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…

2 months ago

Xenon to Report Q3 2025 Financial Results on November 3, 2025

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…

2 months ago

Xenon to Report Q3 2025 Financial Results on November 3, 2025

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…

2 months ago

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival…

2 months ago

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival…

2 months ago
Show more Posts
Show previous Posts